drugset
drugset / Trial / NCT05718895

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

NCT05718895 ↗

Phase 1 Recruiting 156 enrolled Antengene Biologics Limited
NaSequentialOpen-labelTreatment

Summary

This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors

Timeline

Start
2023-03-27
Primary completion
2027-12-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ATG-022 Unknown 0.3 mg/kg —
Subject ATG-022 Unknown 0.9 mg/kg —
Subject ATG-022 Unknown 1.8 mg/kg —
Subject ATG-022 Unknown 2.4 mg/kg —
Subject ATG-022 Unknown 3 mg/kg —
Subject ATG-022 Unknown 3.6 mg/kg —

Indications

No indication recorded.